Krzysztof Brzezinka

Krzysztof Brzezinka has held various roles throughout their work experience. Krzysztof started their career at Politechnika Śląska w Gliwicach as an Ingenieur (BSc) from 2007 to 2010, and later pursued their MSc from 2010 to 2012. Krzysztof then joined the Max Planck Institute for Molecular Genetics in 2012, where they completed their Masterarbeit (MSc). Following this, they enrolled as a PhD student at the University of Potsdam from 2012 to 2016. Moving forward, Brzezinka joined Bayer in 2016 as a Research Scientist & Project Leader until 2019. Krzysztof then worked at MorphoSys as a Clinical Biomarker Scientist from January 2020 to June 2020. Currently, they hold the position of Head of Therapeutic Compound Research Laboratory at NUVISAN The Science CRO since July 2020.

Krzysztof Brzezinka pursued their education at the University of Potsdam from 2012 to 2016. Krzysztof obtained a Research Doctorate in Molecular Biology during this period.